Hemophilia Treatment Market, By Product Type (Plasma Derived Coagulation Factor, Recombinant Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Re

Hemophilia Treatment Market, By Product Type (Plasma Derived Coagulation Factor, Recombinant Coagulation Factor, Antifibrinolytic Agents, and Desmopressin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor such as factor VIII. There are around 13 types of clotting factors that work with blood platelets to help in clotting of blood. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency of factor VIII. Hemophilia B occurs due to deficiency of factor IX, and Hemophilia C is caused due to factor XI deficiency.In most cases, hemophilia is passed down through families that are inherited. It is mostly passed to the male childrens. The primary treatment for hemophilia is to replace the clotting factor in the blood though intravenous infusions. However, high cost of hemophilia treatment, lack of medicines and serious adverse events associated with plasma derived derived products is expected to hinder the market growth. Consequently, rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.

Market Dynamics

Increasing government initiatives towards hemophilia treatment is likely expected to propel the growth of hemophilia treatment market over the forecast period. For instance, according to the article published in National Library of Medicine in June 2021, World Federation of Hemophilia(WFH) started distribution of coagulation factor concentrates and emicizumab in low- and low–middle-income countries through a humanitarian aid program. This programwill hwlp to improve life of a limited number of PWH in the developing world.

Key features of the study:

• This report provides an in-depth analysis of the global hemophilia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hemophilia treatment market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia treatment market

Detailed Segmentation:

• Global Hemophilia Treatment Market, By Product Type:
• Plasma Derived Coagulation Factor
• Recombinant Coagulation Factor
• Antifibrinolytic Agents
• Desmopressin
• Global Hemophilia Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Hemophilia Treatment Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Takeda Pharmaceutical Co., Ltd*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Sanofi S.A.
• Octapharma AG
• Swedish Orphan Biovitrum AB
• Baxter International Inc.
• Biogen Inc
• Bayer AG
• CSL Behring
• Ferring B.V.
• Pfizer, Inc.
• Kedrion
• Novo Nordisk A/S
• F. Hoffmann-La Roche AG

“*” marked represents similar segmentation in other categories in the respective section.